EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudie

Oral tofacitinib in comparison with dexamethasone oral mini-pulse therapy for the treatment of active nonsegmental vitiligo: A randomized controlled trial

Anubha Dev, Keshavamurthy Vinay, Anuradha Bishnoi, Muthu Sendhil Kumaran, Hitaishi Mehta, Davinder Parsad

Journal of the American Academy of Dermatology · 2025

DOI: 10.1016/j.jaad.2025.06.006 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of the American Academy of Dermatology, 2025. Verfasst von Anubha Dev und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. Hauptthemen laut MEDLINE: Vitiligo, Piperidines, Pyrimidines, Dexamethasone. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: There is a lack of literature on stabilizing and repigmenting potential of oral tofacitinib in active vitiligo. OBJECTIVE: To compare the efficacy of oral tofacitinib with oral mini-pulse therapy in active vitiligo. METHODS: This prospective, randomized, investigator-blinded trial recruited patients aged 18-60 with active nonsegmental vitiligo. Participants were randomized to receive dexamethasone 2.5 mg twice a week (group A) or oral tofacitinib 5 mg twice daily (group B) for 24 weeks, followed by 12 weeks of observation. The primary outcome was the proportion of patients showing ≥50% improvement in vitiligo extent score (VES) at 24 weeks. RESULTS: Sixty patients were recruited (30 per group), with 49 completing 36 weeks. At 24 weeks, the proportion achieving ≥50% VES improvement was similar (16.7% vs 20.0%, P = .833). By 36 weeks, group B had a significantly greater VES decrease (31.5 ± 24.9% vs 16.7 ± 34.8%, P = .031). Group A had higher treatment failure at 12 weeks (20% vs 3.3%, P = .049), but comparable stabilization rates at 24 weeks (63.3% vs 83.3%, P = .171). LIMITATIONS: Limited sample size, single-center design, and lack of double-blinding. CONCLUSION: Tofacitinib is more effective than oral mini-pulse (dexamethasone 2.5 mg twice a week) for treating active nonsegmental vitiligo.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

VitiligoPiperidinesPyrimidinesDexamethasonePyrrolesProtein Kinase InhibitorsGlucocorticoidsHumansAdultFemaleMaleMiddle AgedProspective StudiesAdministration, OralYoung AdultAdolescentTreatment OutcomePulse Therapy, DrugSeverity of Illness Index

Stichwörter der Autor:innen

JAK-STAT inhibitorsactivedexamethasone mini-pulsenonsegmental vitiligorepigmentationstabilizationtofacitinib

Substanzen

tofacitinibPiperidinesPyrimidinesDexamethasonePyrrolesProtein Kinase InhibitorsGlucocorticoids

Autor:innen und Institutionen

  • Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
  • Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. Electronic address: vinay.keshavmurthy@gmail.com.

Zitieren

APA

Dev, A., Vinay, K., Bishnoi, A., Kumaran, M. S., Mehta, H., & Parsad, D. (2025). Oral tofacitinib in comparison with dexamethasone oral mini-pulse therapy for the treatment of active nonsegmental vitiligo: A randomized controlled trial. Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2025.06.006

Vancouver

Dev A, Vinay K, Bishnoi A, Kumaran MS, Mehta H, Parsad D. Oral tofacitinib in comparison with dexamethasone oral mini-pulse therapy for the treatment of active nonsegmental vitiligo: A randomized controlled trial. Journal of the American Academy of Dermatology. 2025. doi:10.1016/j.jaad.2025.06.006

BibTeX
@article{Dev2025,
  author = {Dev, Anubha and Vinay, Keshavamurthy and Bishnoi, Anuradha and Kumaran, Muthu Sendhil and Mehta, Hitaishi and Parsad, Davinder},
  title = {Oral tofacitinib in comparison with dexamethasone oral mini-pulse therapy for the treatment of active nonsegmental vitiligo: A randomized controlled trial},
  journal = {Journal of the American Academy of Dermatology},
  year = {2025},
  doi = {10.1016/j.jaad.2025.06.006}
}
Kostenlos starten →